Background
Methods and findings
We developed an immunotherapeutic strategy targeting the CD33 myeloid antigen, expressed in~85-90% of patients with acute myeloid leukemia, using chimeric antigen receptor redirected T-cells. Considering that administration of CAR T-cells has been associated with cytokine release syndrome and other potential off-tumor effects in patients, safety measures were here investigated and reported. We genetically modified human activated Tcells from healthy donors or patients with acute myeloid leukemia with retroviral supernatant encoding the inducible Caspase9 suicide gene, a ΔCD19 selectable marker, and a humanized third generation chimeric antigen receptor recognizing human CD33. ΔCD19 selected inducible Caspase9-CAR.CD33 T-cells had a 75±3.8% (average ± standard error of the mean) chimeric antigen receptor expression, were able to specifically lyse CD33 + targets in vitro, including freshly isolated leukemic blasts from patients, produce significant amount of tumor-necrosis-factor-alpha and interferon-gamma, express the CD107a degranulation marker, and proliferate upon antigen specific stimulation. Challenging ΔCD19 selected inducible Caspase9-CAR.CD33 T-cells with programmed-death-ligand-1 enriched leukemia
Introduction
Approximately fifty percent of patients with acute myeloid leukemia (AML) can be cured with current therapeutic strategies which include, standard dose chemotherapy for patients at standard risk of relapse as assessed by cytogenetic and molecular analysis, or high-dose chemotherapy with allogeneic hematopoietic stem cell transplant (allo-HSCT) for high-risk patients. Despite allo-HSCT about 25% of patients still succumb to disease relapse, therefore, novel strategies are needed to improve the outcome of patients with AML. One approach to decrease disease relapse is to increase the anti-tumor activity of T-cells by genetic redirection, endowing them with a transgenic T-cell receptor (TCR) or a chimeric antigen receptor (CAR) molecule targeting a specific tumor associated antigen. However, TCR redirected T-cells are HLA restricted, and TCR mispairing with the endogenous TCR could result in reduced avidity or unwanted specificities [1] . Alternatively, CARs represent a universal platform for immune-therapy because they are not HLA-restricted, combining the specificity of an antibody with the killing machinery of the T-cell in a single chain [2] , with a minimized risk of chain mispairing. Additionally, recognizing antigens in an HLA independent fashion makes CAR T-cells intrinsically resistant to immune evasion strategies that could arise during antigen processing or presentation [3] . Infusion of CAR.CD19 redirected T-cells has resulted in complete remission/partial remission of lymphoid leukemia, but at the expense of severe cytokine release syndrome and other off-tumor effects [4] . CAR T-cell applications for AML have been investigated in vitro and in mice models [5] targeting CD33 [6] [7] [8] [9] , CD44v6 [10] , CD123 [5, 9, 11, 12] , but only results from small clinical trials targeting Lewis-Y (LeY) [13] , or CD33 [14] have been published to date.
We generated a CAR molecule encoding a humanized anti-CD33 single chain variable fragment (scFv) for the genetic modification of human activated T-cells to target CD33 + AML.
CD33 is a myeloid-specific sialic acid-binding receptor overexpressed on the cell surface of 90% of AML blasts, and it has a role in regulating leukocyte functions in inflammatory and immune responses [15] . CD33 is also expressed on multipotent myeloid precursors, but not all normal hematopoietic stem cells, unipotent colony forming cells, maturing granulocytes and monocytes, peripheral granulocytes and resident macrophages, Kupfer cells and hepatocytes [16, 17] . Therapeutic strategies targeting CD33 with unconjugated antibodies, antibody-drug conjugates, immunotoxins, or radioisotopes, (either monospecific or targeting multiple antigens), have been developed or investigated in the clinical setting, and has been reviewed elsewhere [18] . Unconjugated monospecific antibodies have demonstrated modest activity in AML, with the clinical challenge of the need for continuous intravenous administration in virtue of their short half-life. Gemtuzumab ozogamicin (GO), a humanized CD33 antibody conjugated to a calicheamicin-γ 1 derivative via a hydrolyzable linker, demonstrated clinical activity when given with induction chemotherapy in newly diagnosed AML, with mixed results depending on disease subtype, cytogenetic risk, and patient age. To overcome some of the limitations of GO, such as the non-uniform conjugation of the toxin with the antibody, the drug's relatively slow internalization kinetics, and toxin extrusion via drug transporters, SGN-CD33A, a humanized CD33 antibody with engineered cysteines carrying a synthetic DNA cross-linking pyrrolobenzodiazepine dimer via a protease-cleavable linker, was developed and demonstrated increased potency in vitro against human AML cells while maintaining activity in the presence of drug transporters. Complete remissions were seen in 30% of patients in an ongoing phase 1 study of primarily older adults with relapsed/refractory AML, or those who declined standard intensive therapy for newly diagnosed disease (NCT01902329). CAR T-cells present several advantages over the infusion of therapeutic antibody conjugates, such as the more efficient bio-distribution and persistence, and independence from the multidrug resistance protein. It is unclear whether targeting CD33 with a CAR would result in hepatic toxicity as seen with GO [19, 20] , however, considering that administration of CAR T-cells has been associated with cytokine release syndrome and other potential off-tumor effects in patients [4] , safety measures are here investigated.
To enable elimination of the CAR T-cells in case of severe adverse events (SAEs), we incorporated the intracellular inducible Caspase9 (iC9) suicide gene, composed of a drug binding domain cloned in frame with human Caspase9, with the exogenous administration of a non therapeutic small molecule chemical inducer of dimerization (CID) (AP1903 in vivo, or the analogous AP-20187 for in vitro studies), resulting in iC9 dimerization and apoptosis of the transduced cells within hours. This has been clinically validated by our group [21] [22] [23] , and an imminent phase 1 clinical trial will investigate iC9 and a CAR T-cells redirected against the disialoganglioside GD2 in patients with advanced melanoma (CARPETS, ACTRN12613000198729) [24] .
The iC9 construct also includes a truncated (biologically inert) CD19 (ΔCD19) molecule, serving solely as a selectable marker. Here we validated the functionality of the ΔCD19 selected (sel.) iC9-CAR.CD33 ATCs in vitro, showing their activity against CD33 + AML cell lines or AML cells freshly isolated from patients. Additionally, since the activation of the iC9 suicide gene results in incomplete elimination (~90%) of gene modified cells even after higher doses or repeated administration [25, 26] , we sought to investigate the addition of a second pharmacologic agent together with the dimerizer to enhance elimination. We have previously demonstrated that iC9 resistant cells have higher expression of the anti-apoptotic molecule B-cell lymphoma 2 (BCL-2) [25] , and therefore we investigated whether the co-administration of the dimerizer with an anti-apoptotic small molecule inhibitor would result in complete suicide gene modified cell elimination. We also tested the activity of the lymphotoxic agent mafosfamide. We found that co-administration of ABT-199 [27] , ABT-737 [27] , or mafosfamide [28] with the dimerizer resulted in an additive killing effect on suicide gene modified cells by activating the iC9 safety switch, up to complete elimination of the gene modified cells [29] .
This strategy could be investigated for the safety of CAR T-cell applications, and targeting CD33 could be used as a 'bridge" therapy for patients coming to allogeneic hematopoietic stem cell transplant, as anti-leukemia activity from infusing CAR.CD33 T-cells has been demonstrated in an ongoing clinical trial. [14] Albeit never performed in the clinical setting, our future plan is to investigate the utility of iC9-CAR.CD33 T-cells as part of the conditioning therapy for an allo-HSCT for AML, together with other myelosuppressive agents, whilst the activation of the iC9 suicide gene would grant elimination of the infused gene modified T-cells prior to stem cell infusion to reduce the risk of engraftment failure as the CD33 is also expressed on a proportion of the donor stem cell graft.
Results

Genetic modification of activated T-cells from healthy donors
Activated T-cells (ATCs) were established from five healthy donors and transduced with retroviral supernatant encoding the CAR.CD33 or the iC9-ΔCD19-CAR.CD33 construct, (" Fig 1A  and 1B") . As a control, we cultured non-transduced (NT) ATCs in parallel. As shown in " Fig  1C and 1D" , T-cells transduced with either the CAR.CD33 or the iC9-ΔCD19-CAR.CD33 construct expressed significant levels of CAR-CD33, although the expression was higher in cells transduced with the vector encoding CAR.CD33 alone (52±4.5% vs. 32±3.5%, respectively; average±standard error of the mean (SEM) is reported here and throughout the manuscript unless otherwise specified). However, after ΔCD19 selection of iC9-ΔCD19-CAR.CD33 ATCs, CAR expression was enriched to 75±3.8%. CAR.CD33 and ΔCD19 sel. iC9-CAR.CD33 gene modified ATCs expressed the CAR on both CD4 and CD8 subsets, and the majority of transduced T-cells (~70%) had a terminally differentiated/effector memory phenotype (N = 4-7 experiments from ATCs generated from 5 donors), (" Fig 1E and 1F") .
We evaluated the expression of the human CD33 antigen on freshly isolated peripheral blood mononuclear cells (PBMCs) or ATCs, and we found that 7.7±2.4% of PBMCs (N = 4; 3 donors), and 34±1.5% of NT ATCs (N = 4-5; 4 donors) also expressed the CD33 antigens; however, only 1.1±0.3% of ΔCD19 sel. iC9-CAR.CD33 ATCs expressed the CD33 antigen after three weeks in culture (N = 4-5; 4 donors, "Table A in S1 File"), and residual CD33 negative ATCs were able to expand in vitro. After three weeks in culture the fold expansion was 61±13 for NT, and 59±16 for ΔCD19 sel. iC9-CAR.CD33 ATCs, (N = 5-8, using ATCs from 4 donors, "Figure A in S1 File").
Effector functions
In order to assess whether the expression of a CAR molecule targeting CD33, onto CAR.CD33 ATCs or ΔCD19 sel. iC9-CAR.CD33 ATCs, made them cytotoxic to CD33 + tumor cells, we investigated their function in an in vitro co-culture assay, and a luciferase-reporter cytotoxicity assay. For co-culture assay, we used as a target the MV4-11 CD33 + AML cell line genetically modified to express an enhanced green fluorescent (eGFP) protein, and sorted by fluorescence-activated cell sorting (FACS) to eGFP expression !98%. We then co-cultured the MV4-11 eGFP + cell line overnight with NT, CAR.CD33 or ΔCD19 sel. iC9-CAR.CD33 ATCs at an from 3 donors; P<0.01 (CAR.CD33), and P<0.001 (ΔCD19 sel. iC9-CAR.CD33) vs. NT ATCs, respectively), (" Fig 2A" ). In addition, by gating on the eGFP + target cells, we estimated that co-cultures employing CAR.CD33 ATCs resulted in 98.2±0.9% reduction of CD33 expressing targets, and co-cultures employing ΔCD19 sel. iC9-CAR.CD33 ATCs resulted in 99 ±0.6% reduction of CD33 expressing targets, as compared with co-cultures employing NT ATCs, (N:3 from 3 donors; P<0.01 (CAR.CD33), and P<0.001 (ΔCD19 sel. iC9-CAR.CD33) vs. NT ATCs, respectively), (" Fig 2A" ). for ΔCD19 sel. iC9-CAR.CD33 ATCs (N:3 from 3 donors; P<0.01 vs. NT ATCs for both). Dot-plots from a representative experiment are shown in "Fig 2A" , whereas a summary of the results is represented in the " Figure B in S1 File". We also assessed the ability of CAR redirected ATCs to kill CD33 + targets in an in vitro firefly-luciferase-based cytotoxicity assay.
After overnight incubation with MV4-11 eGFP-Firefly Luciferase + (ffLuc) target cells at an effector:target ratio of 10:1, we observed 99.3±0.4% killing when using CAR.CD33 ATCs as effectors, and 98.3±0.5% killing when using ΔCD19 sel. iC9-CAR.CD33 ATCs as effectors, (N: 3-7 from 5 donors; P<0.05, and P<0.001 vs. NT ATCs, respectively); significant killing was maintained until the 1.25:1 ratio, and a summary of the results is depicted in " Fig 2B" .
Next, we assessed the ability of CAR redirected ATCs to release the lysosomal-associated membrane protein-1 (LAMP-1 or CD107a), a marker of CD8 + T-cell degranulation. For this aim, following stimulation with CD33 + targets, we performed intracellular cytokine staining with a CD107a antibody. We found that CAR.CD33 expressed CD107a at a 4.7±1.0 folds higher than NT ATCs, and ΔCD19 sel. iC9-CAR.CD33 expressed CD107a at a 3.9±0.7 folds higher than NT ATCs, (N:4-6 from 4 donors; P<0.05 vs. NT ATCs for both), (" Fig 2C" ).
To evaluate the proliferative response of CAR redirected ATCs in response to CD33 + target stimulation in vitro, we co-cultured effectors with irradiated MV4-11 cell line at an effector:target ratio of 1:1 for 5 days, without exogenous cytokines administration. CAR redirected ATCs exhibited a dilution of the carboxyfluorescein succinimidyl ester (CFSE) dye at a higher extent as compared with NT, as per proliferation in response to CD33 + target, (" Fig 2D" ). ±1.0;17±17 pg/mL). IL-17A production was below 5 pg/mL; (mean±SEM of 3-9 independent experiments from 3-4 different donors), (" Fig 2E" ). Target cells only resulted in a cytokine production below 5 pg/mL for all tested cytokines. Therefore, CAR.CD33, and ΔCD19 sel. iC9-CAR.CD33 ATCs demonstrated potent effector functions towards CD33 + leukemia cell lines.
CAR.CD33 and ΔCD19 sel. iC9-CAR.CD33 ATCs eliminated freshly isolated blasts in vitro
We sought to investigate whether CAR.CD33 and ΔCD19 sel. iC9-CAR.CD33 ATCs would result in the killing of CD33 + leukemia blasts freshly isolated from the peripheral blood or the bone marrow of patients with AML. The percentage of CD33 expression analyzed on AML samples from 14 patients is displayed in " Fig 3A" , and reported in " Table 1 Effector ATCs generated from healthy donors stimulated with samples from patients with AML in vitro for 4 hours showed an increased expression of the CD8 + T-cell degranulation marker CD107a, with a 4.7±1.5-fold increase for CAR.CD33 as compared with NT (N = 8), and a 5.4±1.7-fold increase for ΔCD19 sel. iC9-CAR.CD33 as compared with NT, (N:8-12 from 4 donors; P<0.05 for both), (" Fig 3D" ). Co-culture employing CAR.CD33 or ΔCD19 sel. iC9-CAR.CD33 ATCs as effector resulted in a robust secretion of IFN-γ (NT: 641±160, CAR. CD33: 2,218±418, or ΔCD19 sel. iC9-CAR.CD33: 1,353±177 pg/mL; P<0.01 vs. NT ATCs for both CAR.CD33 and ΔCD19 sel. iC9-CAR.CD33 ATCs), and TNF-α (215±69; 1,120±385; 832 ±183 pg/mL; P<0.05, and P<0.001 vs. NT ATCs, respectively). For each respective condition noted above, other cytokines were detected as follows: IL-6 (237±94; 29±10; 162±84 pg/mL), IL-2 (116±20; 79±27; 38±5.8 pg/mL; P<0.05, and P<0.01 vs. NT, respectively), IL-10 (110±57; 21±15; 243±62 pg/mL), and IL-4 (6.7±3.2; 8.8±6.3; 13±4.7 pg/mL). IL-17A production was below 5 pg/mL in each co-culture; (mean±SEM from 5-18 experiments from 4 different ATC donors), (" Fig 3E" ).
In order to assess whether it would be feasible to translate this strategy into the clinical setting, we were able to successfully generate CAR.CD33 or ΔCD19 sel. iC9-CAR.CD33 ATCs using PBMC isolated from patients with AML. "Fig 4" shows the phenotypic characteristics and cytotoxic activity of NT, CAR.CD33 and ΔCD19 sel. iC9-CAR.CD33 ATCs generated from two patients with AML (patients#3, and #U). Fold expansions from ATC generated from these two patients after three weeks of culture were 100±66 for NT, 60±10 for CAR.CD33, and 66±16 for ΔCD19 sel. iC9-CAR.CD33 ATCs, ("Figure C in S1 File"). We tested the cytotoxic activity of ATCs generated from patient#3 after overnight incubation with the CD33 + MV4-11-eGFP + cell line, in the presence of culture medium or in the presence of patient's autologous plasma. ATCs generated from patient#3 proved functional, resulting in the elimination of CD33 + targets after overnight co-culture (CAR.CD33: 98±2.0%; or ΔCD19 sel. iC9-CAR.
CD33: 98±2.5%, vs. NT ATCs), and the presence of patient's plasma did not impair the killing activity of ATCs (CAR.CD33: 99±1.1%, or ΔCD19 sel. iC9-CAR.CD33: 100±0.07%, vs. NT ATCs), (" Fig 4B" , left panels). ATCs generated from patient#3 resulted also in the elimination of PKH + labeled CD33 + autologous targets (CAR.CD33: 89±0.6%; or ΔCD19 sel. iC9-CAR.
CD33: 89±0.004%, vs. NT ATCs), and the presence of patient's plasma did not impair the killing activity of ATCs (CAR.CD33: 97±1.1%, or ΔCD19 sel. iC9-CAR.CD33: 98±0.6%, vs. NT Suicide Gene Modified anti-CD33 CAR T-Cells for AML ATCs), (" Fig 4B" , right panels). ATCs derived from patient#U were also functional ("Figure D in S1 File"). Cell elimination was due to apoptosis as assessed by Annexin V/7-AAD staining performed 4 hours from the beginning of the co-culture ("Figure E in S1 File"). Next, we sought to investigate whether patient samples expressing the programmed cell death ligand 1 (PD-L1) would prevent cellular killing from CAR redirected ATCs. Therefore, in a pilot experiment, we sorted PD-L1 + or PD-L1 neg patient blasts by FACS (patient#T), for co-culture assay with NT, CAR.CD33, or ΔCD19 sel. iC9-CAR.CD33 ATCs. We observed that CAR.CD33, or ΔCD19 sel. iC9-CAR.CD33 ATCs efficiently killed PD-L1 neg targets, as well as PD-L1 + targets, (" Fig 5A" ). The percentage of programmed cell death 1 (PD-1) expression on T-cells co-cultured with PD-L1 + AML blasts were 10% (CAR.CD33), or 24% (ΔCD19 sel.
iC9-CAR.CD33), while the percentage of PD-1 expression on T-cells co-cultured with PD-L1 neg AML blasts were 11% (CAR.CD33), or 18% (ΔCD19 sel. iC9-CAR.CD33), (" Fig   5B" ). 
Impact of CAR redirected ATCs on hematopoietic colony formation
In order to address whether suicide gene modified anti-CD33-CAR-redirected-ATCs would impair hematopoietic colonies formation, we used a standard in vitro hematopoietic colony formations assay. We co-cultured NT or ΔCD19 sel. iC9-CAR.CD33 ATCs with CD34 + enriched human hematopoietic stem cells (HSC). We seeded 400,000 effector cells and 100,000 CD34 + HSC (effector:target = 4:1). After overnight co-culture, we sorted CD34 + HSC by lineage negative depletion, and enumerated the remaining number of CD34 + HSC by flow cytometry. We found that the number of CD34 + HSC decreased from 9,318±4,413 when using NT as effectors, to 4,213±1,719 when using ΔCD19 sel. iC9-CAR.CD33: as effectors; P = 0.41 (N = 4 experiments in duplicate using ATCs generated from 2 healthy donors), (" Fig 6A" ).
After co-culture, we plated the same number of residual lineage negative depleted CD34 + HSC in cytokine conditioned semisolid medium in vitro. We found that HSC co-cultured with Suicide Gene Modified anti-CD33 CAR T-Cells for AML ΔCD19 sel. iC9-CAR.CD33 ATCs retained the capability to proliferate and differentiate in cytokine conditioned semisolid medium. In fact, we scored that erythroid burst/colony forming units were 36±13; 37±17, when using NT, or ΔCD19 sel. iC9-CAR.CD33 effectors, respectively, granulocyte-macrophage colony forming units were 40±14 vs. 30±9.2, and granulocyteerythroid-macrophage-megakaryocyte colony forming units were 12±2.9 vs. 7.5±1.3, respectively, (" Fig 6B" ).
Conditional elimination of ΔCD19 sel. iC9-CAR.CD33 ATCs
Finally, we sought to quantify the degree of CAR redirected ATCs elimination after activation of the iC9 suicide gene for safety. We performed an in vitro killing assay with NT, CAR.CD33 or ΔCD19 sel. iC9-CAR.CD33 treated or untreated overnight with a small molecule CID (AP20187), that activated the iC9 safety switch with resulting apoptosis of gene modified cells.
After overnight exposure to CID [10 nM] in vitro, the killing effect on NT ATCs or CAR.CD33 ATCs was negligible with only 1.7±0.6%, and 0.3±0.7% cell elimination, respectively, whereas the elimination of iC9 suicide gene modified CAR T-cells was 76.4±2.0%, (P<0.001).
We tested the CID at a concentration of 14.2 ng/mL [10 nM] because this concentration resulted in maximal killing (plateau) in vitro [30] . In vivo the peak concentration assessed in healthy volunteer donors after the therapeutic dose of 0.5 mg/kg was 626 ng/mL declining after 2-4 hours. [31] In our current in vitro experiments, we observed that iC9 resistant cells maintained CAR expression (80.9±2.1%), albeit at a dimmer intensity ("Figure F in S1 File"), and, considering Suicide Gene Modified anti-CD33 CAR T-Cells for AML the need to completely eliminate the CAR T-cells in case of SAEs, we aimed here to develop a strategy that completely eliminated iC9-CAR + T-cells. Since we have previously reported that even increasing the concentration of the CID in both in vitro [30] ±2.1% (P < .05), when treating ΔCD19 sel. iC9-CAR.CD33 ATCs, when used at used at 0.5 or 2 μg/mL, respectively (" Fig 7A" ). Afterwards, cells from each condition were re-plated with fresh T-cell culture medium in the presence of 50 I.U. /mL recombinant human IL-2 (rh-IL2), and cultured for 4-7 more days, followed by 7-AAD staining to assess their viability. A schematic representation of the experimental procedure is depicted in " Fig 7B" (left panel). At this second point analysis, the combination of either ABT-199 or ABT-737 at 2 μM together with the CID, resulted in !98% suicide gene modified CAR ATCs cells elimination (P < .01; P < .05, respectively), increasing to 100% when used at 10 μM. Mafosfamide at 0.5 μg/mL (with CID [10 nM]), resulted in 97.4% elimination of suicide gene modified CAR ATCs (P < .01), and 99% when applied at 2 μg/mL. Representative histograms displaying the number of viable cells (7-AAD neg ) are shown in " Fig 7B" (right panels), and a summary of the results is represented in the "Figure G in S1 File".
Discussion
Chimeric antigen receptor redirected T-cells are an emerging powerful tool for the treatment of patients with cancer. Particularly encouraging results were demonstrated when infused CAR T-cells redirected against the CD19 antigen in patients with relapsed/refractory acute lymphoblastic leukemia resulted in a high-rate of long-lasting complete remissions. Interestingly, CAR T-cells were able to effectively expand in vivo in these patients, and disease responses were observed as early as 7 days after CAR T-cell infusion [4] .
In contrast, the clinical experience with CAR T-cells in patients with AML is still extremely limited. Only the results from two small clinical trials have been published to date. In one trial, patients received infusion of autologous activated T-cells engineered to express a second generation CAR targeting the Lewis Y (LeY or CD174) difucosylated carbohydrate antigen. LeY is a blood group antigen shown to be present also on hematopoietic progenitors (CD34 + cells), on AML blasts and epithelial cancers [13] . Four patients were treated on this clinical trial, three with minimal residual disease consisting of persisting cytogenetic alterations, and one with active disease. The patients received a median number of 1.1x10 9 (range 5x10 8 -1.3x10 9 ) T-cells with a 14-38% CAR expression, as assessed by flow cytometry. In these patients, T-cells were able to expand in vivo (~1,200 transgene copies/1,000 cells in the peripheral blood), persisted up to 10 months, and efficiently homed to bone marrow and sites of leukemia cutis. Regarding clinical activity, one patient was able to achieve cytogenetic remission, another experienced a reduction in peripheral blast count, and one patient had a protracted remission of disease. No serious adverse events were observed despite the increased production of interferon-gamma detected in two patients. It is possible that the limited clinical efficacy could be secondary to the low intensity of expression of the LeY antigen on AML blasts, which is more strongly expressed on tissues of epithelial origin.
A second clinical trial infused autologous T-cells bearing a second generation CAR targeting the CD33 antigen in a patient with refractory AML and the presence of active disease. This patient received 1.12x10 9 T-cells with a 38% CAR expression. This patient experienced mild cytokine release syndrome and a marked decrease in bone marrow blasts (from >50% to <6%) two weeks after infusion; however, this was followed by florid progression nine weeks after the T-cell infusion. Interestingly, CAR T-cells were still present in the patient's peripheral blood and were able to kill in vitro leukemia cells previously isolated from the same patient. Antigen down-regulation was not the implicated mechanism of tumor evasion, since the patient blasts still highly expressed CD33 at progression. The authors postulated that leukemia cells might have adopted other immune-evasion strategies enabling them to escape the killing by CAR.CD33 ATCs. Additionally, considering the transient but significant tumor response, the authors suggested that CAR.CD33 T-cells could be used as a 'bridge' to an allo-HSCT [14] , thus rescuing possible off-target myelotoxic effects of the CAR.CD33 T-cells with the HSCT. Although we did not observe a significant elimination of hematopoietic stem cells in vitro, CAR T-cells targeting CD33 could exacerbate anemia and thrombocytopenia in virtue of CD33 expression on these hematopoietic progenitors, as previously observed in preclinical models in vitro [6] [7] [8] , or in vivo [9] . Although our in vitro data conflicts with those previous reports, a direct comparison of the results from different studies from different centers is difficult because of different details in the performance of these assays, stem cell source, effector to target ratio, and incubation time. It is also possible that CD33 negative cells may reacquire CD33 expression during hematopoietic development, as demonstrated for CD123 negative hematopoietic progenitors [5] . In fact, conflicting results have been reported between different centers regarding other targeted antigens. CAR.CD123, for example, whereas some authors demonstrated no impact, of CAR.CD123 on myeloablation when compared with untransduced T-cells or controls [9, 11] , others have shown the ability to cause myeloablation in xenogeneic HSCT mice models [5, 12] , and have proposed its use as conditioning to an allo-HSCT.
Clinical trials will be helpful in understanding the impact of targeting CD33 with CAR ATCs on myelosuppression. In the only CAR.CD33 ATCs clinical case reported in literature, the patient was already neutropenic (0.4-1. The authors concluded that the observations from this patient should undoubtedly make us rethink that irreversible myelosuppression and neutrophil deficiency may not be an unsurpassable hurdle for CAR.CD33 T-cell therapy. Additionally, only a transient hyperbilirubinemia within 2 weeks of CAR.CD33 T-cell infusion was observed in this patient. This trial is still ongoing, and data from a larger group of patients is needed. Of note, the cytotoxic activity was modest in vitro [14] . In contrast, in our in vitro data the cytotoxic activity was robust; this may relate to the presence of additional co-stimulatory domains in our CAR (3 rd generation construct), the affinity/avidity profile of the scFv, or the T-cell generation protocol. For example, unlike our short-term culture in vitro, T-cells cultured long-term may exhibit a phenotype consistent with an exhausted state when using a protocol that expands the cells in vitro over a protracted period of time. Additionally, our CAR.CD33 was able to lyse CD33 + primary AML samples in vitro even when expressing CD33 at low levels, as previously reported by Pizzitola et al. [9] , a finding attributed to the high affinity of the scFv used in the CAR, as in ours.
One additional immune-evasion strategy to take into account is correlated with the expression and/or secretion of an immune checkpoint molecule, such as the PD-L1 molecule by AML cells [32] [33] [34] . In our in vitro co-culture experiments we observed cytotoxic activity from CAR T-cells challenged with either PD-L1 neg or PD-L1 + AML blasts, although it is possible that in the in vivo milieu, this mechanism could contribute to increased T-cell apoptosis for binding the respective receptor on T-cells, as PD-1 + CD8 T-cells were found to increase in AML metastatic site in vivo [35] . Additionally, it is possible that anti-leukemia treatments could further increase immuneevasion mechanisms adopted by tumor cells, and therefore PD-1/PD-L1 blockade could result in an enhanced therapeutic response. In fact, in vitro application of the CD3/CD33 engaging bispecific antibody resulted in up-regulation of PD-L1 expression on primary AML cells, upregulation of PD-1 expression on T-cells, with reversal of the killing inhibition through PD-1/ PD-L1 blockade [36] . The impact on the removal of CD33 + cells, including the potential for myelosuppression, or immune-defects from targeting CD33 + memory T-cells will need to be investigated. It would be meaningful to incorporate CAR T-cells as a mean of conditioning for an allo-HSCT, which could reduce the toxic effects of high-dose chemotherapy while exerting a potential positive impact on the quality of life [37] . Additionally, it could enable older patients, or patients with comorbidities to become eligible for an allo-HSCT.
Targeting a myeloid associated antigen could result in myelosuppression, but if used in conjunction with allo-HSCT, it could favorably impact the risk of disease relapse considering the clonal complexity of AML, where relapse can manifest due to the persistence of a leukemic clone, or by the acquisition of additional mutations in pre-leukemic stem cells which are contained within stem cells with a normal phenotype [38] [39] . In this scenario, the application of a suicide gene is essential to completely eliminate the infused T-cells before transplant, therefore reducing the potential risk of engraftment failure from targeting a proportion of the infused CD34
+ hematopoietic stem cells that will express CD33. Another group has proposed the use of CAR T-cells bearing a 'biodegradable', transiently expressed mRNA CAR construct targeting CD33, delivered by the means of electroporation. They demonstrated the ability to control AML tumor growth in vitro and in vivo in mice, as well as the ability to induce myelosuppression in a humanized HSCT mice model [12] . It will need to be investigated in a clinical trial whether the limited persistence of mRNA CAR T-cells would exert a sufficient impact on the leukemia tumor burden. The authors are proposing to perform repeated administration of mRNA CAR T-cells to obviate to the limited persistence of the CAR expression. Another potential side effect of repeated administration of CAR T-cells has been observed in a previous clinical study where patients receiving T-cells electroporated with anti-mesothelin mRNA CAR bearing a mouse anti-human scFv experienced anaphylaxis from the development of antimouse antibodies [40] .
Considering that the activation of the iC9 may result in sparing of a proportion of the CAR T-cells, we have investigated the incorporation of additional pharmacologic agents in order to render a more complete elimination of the gene modified cells. Since in our current in vitro experiments we observed that iC9 resistant cells maintained CAR expression, albeit at a dimmer intensity, we are planning to investigate in a dedicated project, the function of iC9-CAR + resistant cells (cytotoxicity, cytokine profile after re-stimulation with antigen specific targets).
In our current investigation we focused on obtaining 100% iC9-CAR + cell elimination, in order to avoid the risk of graft failure. Our previous work in both animal models [25] and patients [26] has consistently demonstrated that higher dose or repeated administration of the dimerizer to activate the safety switch did not result in complete elimination of iC9 transduced cells. Our earlier studies also suggested that high levels of transcription of the iC9 transgene caused by TCR activation in alloreactive T-cells explain the selective elimination of these cells by the dimerizer in patients who have clinical evidence of acute graft versus host disease [21] . Chang et al. [41] proposed that it is plausible that a dynamic process such as TCR stimulation rather than static repression mechanisms, such as epigenetic marks, affects gene promoters proximal to vector insertion sites promoting their transition from transcriptionally paused promoters to released promoters. TCR stimulation may thus indirectly modulate iC9 expression by alleviating transcriptional repression from nearby host promoters and promote iC9 mRNA expression with resulting selection of a subset of T-cells with proviral integration sites that favor low gene expression. Mutations in the iC9 molecules were not found to exert significant contribution to the dimerizer resistance [41] . Another possible mechanism of resistance is the selection of cells with an imbalance favoring anti-apoptotic factors over pro-apoptotic factors. In fact, we have previously demonstrated that iC9 resistant cells have higher expression of the anti-apoptotic molecule BCL-2 [25] . Therefore, in addition to searching for additional pharmacologic agents able to grant complete elimination of iC9 T-cells, we decided to investigate the impact of agents able to inhibit anti-apoptotic factors. We observed an additive effect on T-cell elimination when combining the BCL-2 inhibitor ABT-199, with the dimerizer to activate the iC9 suicide gene, at a concentration comparable to bioequivalent doses obtained in patients at currently investigated therapeutic doses [42] . Clinical safety data from the performed trial showed that ABT-199 had modest impact on myelosuppression, except for grade 3-4 neutropenia in 41% of patients [42] . ABT-199 is an agent currently being investigated for the treatment of AML [27] , and it would be interesting to use targeted therapy sequentially with CAR T-cells, in order to exert a synergistic effect on resistant leukemia clones [43] . We also added, at a similar concentration, the pan-BCL inhibitor ABT-737 which resulted in a potent lymphotoxic effect as well [29] . These drugs could also result in the elimination of nongene modified T-cells, therefore alternative strategies to enhance the elimination of only iC9 suicide gene modified T-cells are needed, and are currently under investigation in our lab. It remains to be demonstrated whether BCL-2 inhibitors would exert a superior killing effect (albeit not completely sparing normal T-cells), on iC9-cells resistant to AP1903, in virtue of their higher BCL-2 expression. Additionally, although cells can develop an escape mechanism by up-regulating alternative anti-apoptotic molecule, this is unlikely to develop during short-term treatment, and furthermore, the killing effect observed with this agent when combined with the dimerizer was profound.
It is unlikely that BCL-2 mediates its anti-apoptotic effects through direct interaction with iC9. Other possible negative checkpoints in the Caspase 9 activation pathway involve the interaction between the BIR-3 domain of XIAP with Caspase9 and Caspase3, [44] as well as the interaction of BCL-XL with APAF-1, [45] although the latter is bypassed by inducing iC9 with exogenous administration of the dimerizer. We also found that co-administration of mafosfamide [28] was able to exert a more profound elimination of suicide gene modified T-cells, as compared to the CID alone, a relevant finding since the bio-equivalent dose resulting from the administration of intermediate-doses [1.5-2,000 mg/mq] of cyclophosphamide could be incorporated as part of a reduced intensity preparative chemotherapeutic regimen [28] .
In summary, we show here the pre-clinical activity of a third generation CAR targeting the CD33 antigen for AML. We co-expressed an iC9 suicide gene for safety, and were able to completely eliminate suicide gene modified T-cells through the administration of a non-therapeutic dimerizer agent and an additional targeted agent.
Although we are aware and have planned to prove the efficacy and safety of our anti-CD33. CAR transduced ATCs in a murine xenogenic model, our results indicate that this strategy could be investigated for the safety of CAR T-cells applications. Additionally, anti-CD33 redirected CAR T-cells could be used as a 'bridge" therapy for patients coming to an allo-HSCT, as anti-leukemia activity from infusing CAR.CD33 T-cells has been demonstrated in an ongoing clinical trial. [14] Finally, albeit never performed in the clinical setting, our future plan is to investigate the utility of iC9-CAR.CD33 T-cells as part of the conditioning therapy for an allo-HSCT for AML, together with other myelosuppressive agents, whilst the activation of the iC9 suicide gene would grant elimination of the infused gene modified T-cells prior to stem cell infusion to reduce the risk of engraftment failure as CD33 is also expressed in a proportion of the donor stem cell graft. 
Materials and Methods
Tumor cell lines and patient samples
Retroviral constructs
CD33 chimeric antigen receptor (CAR.CD33).
In order to generate the CAR.CD33 construct, we synthesized a humanized anti-CD33 scFv, retrieved from Patent US 8,747,851, using G-block technique (IDT Technologies, Coralville, Iowa), inserting a CD8 alpha protein leader sequence upstream. The synthesized construct was then ligated into SFG-X-CD28-OX40z retroviral vector (kindly provided by Dr. J. Maher (King's College of London)) [46] , using restriction nucleases technique.
Inducible Caspase9 vector with truncated (non-functional) CD19 and CD33 chimeric antigen receptor (ΔCD19 sel. iC9-CAR.CD33). For the iC9-ΔCD19-CAR.CD33vector, we generated a construct encoding the iC9 suicide gene and the ΔCD19 selectable marker (patent US9089520), as well as the CAR.CD33 vector co-expressed through the incorporation of the 2A sequence from Thosea Asigna virus using restriction nucleases technique.
Luciferase vectors. The generation of retrovirus vectors encoding the fusion protein eGFP-ffLuc has previously been described. [47] Transduction of human ATCs. To transduce human ATCs replication incompetent retroviral supernatant was prepared by transfecting 293T with DNA encoding our construct of interest, the Peg-Pam-e plasmid containing the sequence for MoMLV gag-pol, and the DRF plasmid containing the sequence for the RD114 envelope, as previously described. [48] Supernatant harvested at 48 or 72 hours post transfection was used to transduce human ATCs. ATCs were generated using PBMCs from healthy volunteer donors or patients with CD33 Ten to fifty thousand viable and dead events were acquired (the same number of events was acquired within each experiment). 
